TY - JOUR
T1 - Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia
T2 - Review of forty cases
AU - Przepiorka, Donna
AU - Giralt, Sergio
AU - Khouri, Issa
AU - Champlin, Richard
AU - Bueso-Ramos, Carlos
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1998
Y1 - 1998
N2 - The role of allogeneic marrow transplantation as treatment of myeloproliferative disorders other than chronic myelogenous leukemia is not yet determined. At our center, 1 patient with primary myelofibrosis, 1 with mastocytosis, and 4 with myeloid metaplasia have been transplanted using HLA- identical sibling donors. All patients engrafted with full donor chimerism, and morphologic and cytogenetic manifestations of disease in the marrow resolved posttransplant. Three patients died; two with relapse and one from infection. The other three patients are alive in remission at 24+, 28+, and 32+ months posttransplant. Including these cases, a total of 40 patients transplanted for myeloproliferative disorders have been reported. The most common indications for transplantation were cytopenias, increasing blasts in marrow or blood, uncontrolled counts on conventional therapy, poor prognosis cytogenetics, organ dysfunction, and consolidation after induction therapy for blast transformation. Using the outcome data published for these patients, the actuarial estimate of 3-year survival is 55% (95% C.I., 44- 76%) with a median reported follow-up of survivors of 21 months (range, 4- 158 months). For patients with myeloproliferative disorders and evidence of accelerated disease, HLA-identical marrow transplantation is well tolerated and can result in an extended disease-free survival.
AB - The role of allogeneic marrow transplantation as treatment of myeloproliferative disorders other than chronic myelogenous leukemia is not yet determined. At our center, 1 patient with primary myelofibrosis, 1 with mastocytosis, and 4 with myeloid metaplasia have been transplanted using HLA- identical sibling donors. All patients engrafted with full donor chimerism, and morphologic and cytogenetic manifestations of disease in the marrow resolved posttransplant. Three patients died; two with relapse and one from infection. The other three patients are alive in remission at 24+, 28+, and 32+ months posttransplant. Including these cases, a total of 40 patients transplanted for myeloproliferative disorders have been reported. The most common indications for transplantation were cytopenias, increasing blasts in marrow or blood, uncontrolled counts on conventional therapy, poor prognosis cytogenetics, organ dysfunction, and consolidation after induction therapy for blast transformation. Using the outcome data published for these patients, the actuarial estimate of 3-year survival is 55% (95% C.I., 44- 76%) with a median reported follow-up of survivors of 21 months (range, 4- 158 months). For patients with myeloproliferative disorders and evidence of accelerated disease, HLA-identical marrow transplantation is well tolerated and can result in an extended disease-free survival.
KW - Allogeneic bone marrow transplantation
KW - Hypereosinophil syndrome
KW - Myelofibrosis
KW - Myeloid metaplasia
KW - Myeloproliferative disorders
KW - Polycythemia vera
UR - http://www.scopus.com/inward/record.url?scp=0031963620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031963620&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1096-8652(199801)57:1<24::AID-AJH4>3.0.CO;2-3
DO - 10.1002/(SICI)1096-8652(199801)57:1<24::AID-AJH4>3.0.CO;2-3
M3 - Article
C2 - 9423812
AN - SCOPUS:0031963620
SN - 0361-8609
VL - 57
SP - 24
EP - 28
JO - American journal of hematology
JF - American journal of hematology
IS - 1
ER -